Claim BonusDefense Says Sam Bankman-Fried May Not Testify Without ADHD Medication
Sam Bankman-Fried’s lawyers sent a letter to a federal judge on Sunday requesting to allow attention deficit hyperactivity disorder (ADHD) medication, he can’t focus on the lawsuit without it. The defense has growing concerns that Sam Bankman-Fried may not testify without a 12-hour extended-release 20 mg dose before moving him to the courthouse for trial.
Sam Bankman-Fried Can’t Testify Without Medication
According to a court filing on October 15, attorneys for Sam Bankman-Fried submitted a letter to Judge Lewis A. Kaplan seeking his prescribed dose of ADHD medication Adderall during trial hours. Lawyers said Sam Bankman-Fried is not able to focus without his prescribed medication. The lawyers have discussed it with the Court and Government, but they showed less effort to address the issue.
“The defense has a growing concern that because of Mr. Bankman-Fried’s lack of access to Adderall he has not been able to concentrate at the level he ordinarily would and that he will not be able to meaningfully participate in the presentation of the defense case.”
The defense asserts they have received no response to numerous emails and voice messages while attempting to resolve the issue with the BOP. As the trial resumes on October 16, SBF will need a 12-hour extended-release 20 mg dose of Adderall. However, there is no way of knowing currently whether the extended-release dose is effective for Sam Bankman-Fried.
Alternatively, the Court can issue an order permitting Sam Bankman-Fried to take his prescribed Adderall at the courthouse on trial days.
Moreover, the defense requested the court to adjourn the trial for a day on October 17. This will give the defense an extra day to resolve the issue while giving attorneys more time to prepare for trial.
Also Read:
- Tron’s TRX Enters Top Ten Crypto List, What’s Cooking?
- Shibarium Hits New Milestone as Staked BONE Now at ATH
- US DOJ Contradicts SBF Attorney’s Request To Probe Witnesses
Why Trust CoinGape
CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights Read more… to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.
Delivered every day.
- Insights that move markets
- 100,000 active subscribers
Related Articles
- Bitcoin Rises to $94k as Trump Signals Alternatives Ahead of Supreme Court Tariffs Ruling
- Rick Rieder’s Fed Chair Odds Rise as BlackRock CIO Calls for Rates to Fall to 3%
- Fed Rate Cut: Trump Calls for Powell to Lower Rates After Soft CPI Inflation Report
- Breaking: U.S. CPI Inflation Comes In At 2.7%, Bitcoin Rises
- Bitget Launches One-Click Bot Copying for Crypto Users as Algorithmic Trading Goes Mainstream
- Bitcoin Price Eyes $100k as Core US Inflation Slips Ahead of CLARITY Act Markup
- Why Is MSTR Stock Price Down Despite Recent Bitcoin Purchase
- Pi Coin Price Prediction: How Mainnet Migration and New Tokens Supply Could Affect Pi Network?
- Crypto Stocks To Watch: MSTR, Metaplanet, and S&P 500 price
- Solana Price Targets $200 as WisdomTree Declares Its Dominance Structural
- Bitcoin Price Prediction Amid DOJ Probe as Powell Indictment Fears Cool
